Citi lowered the firm’s price target on Apellis to $60 from $67 and keeps a Buy rating on the shares post the Q1 report. The analyst says the “disparate commentary” around share capture needs to be taken in context as while Astellas points to 25% current share ramping to 40%, contrasted with Apellis’ stated 85% share, Astellas uses vials distributed whereas Apellis uses patients treated, hence metrics are not equivalent.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
- Biotech Alert: Searches spiking for these stocks today
- Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- Jefferies view on safety of Apellis’ Syfovre remains unchanged
Questions or Comments about the article? Write to editor@tipranks.com